Research Analysts Offer Predictions for CNXU Q3 Earnings

Conexeu Sciences Inc. (NASDAQ:CNXU) – Equities research analysts at HC Wainwright issued their Q3 2026 earnings estimates for shares of Conexeu Sciences in a report issued on Monday, June 22nd. HC Wainwright analyst S. Ramakanth anticipates that the company will earn ($0.10) per share for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. HC Wainwright also issued estimates for Conexeu Sciences’ Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($0.40) EPS, Q1 2027 earnings at ($0.12) EPS, Q2 2027 earnings at ($0.13) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.15) EPS, FY2027 earnings at ($0.53) EPS, FY2028 earnings at $1.02 EPS, FY2029 earnings at $1.70 EPS and FY2030 earnings at $2.52 EPS.

Separately, Wall Street Zen raised shares of Conexeu Sciences to a “hold” rating in a report on Saturday, May 30th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat.com, Conexeu Sciences currently has an average rating of “Buy” and a consensus price target of $20.00.

Conexeu Sciences Stock Down 6.6%

NASDAQ:CNXU opened at $10.24 on Tuesday. Conexeu Sciences has a 52 week low of $9.60 and a 52 week high of $18.79.

Insider Transactions at Conexeu Sciences

In related news, Director Lynn Sebastian Purcell acquired 202,500 shares of the stock in a transaction dated Thursday, June 18th. The stock was acquired at an average cost of $0.80 per share, with a total value of $162,000.00. Following the purchase, the director directly owned 2,734,240 shares of the company’s stock, valued at approximately $2,187,392. This trade represents a 8.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Conexeu Sciences News Roundup

Here are the key news stories impacting Conexeu Sciences this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on Conexeu Sciences and reaffirmed a $20 price target, signaling bullish expectations for the shares. Conexeu Sciences stock page
• Neutral Sentiment: The firm’s updated estimates still point to losses in the near term, including FY2026 EPS of $(0.40) and FY2027 EPS of $(0.53), which suggests investors should expect continued spending before profitability. Conexeu Sciences stock page
• Positive Sentiment: HC Wainwright’s longer-range forecasts turn sharply better, with EPS projected to improve to $1.02 in FY2028, $1.70 in FY2029, and $2.52 in FY2030, implying a meaningful growth trajectory if execution improves. Conexeu Sciences stock page
• Neutral Sentiment: The new quarterly estimates for Q3 2026 through Q4 2027 remain negative, but the sequence shows gradual improvement over time, which may help support investor sentiment. Conexeu Sciences stock page

Conexeu Sciences Company Profile

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory.